{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T18:13:49Z","timestamp":1776190429498,"version":"3.50.1"},"reference-count":47,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,4,22]],"date-time":"2025-04-22T00:00:00Z","timestamp":1745280000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Lynch syndrome is the most common hereditary colorectal cancer (CRC) syndrome, accounting for 3\u20135% of all CRC cases. Situs inversus totalis (SIT) is a rare congenital malformation with an incidence of 1 in 8,000 to 1 in 25,000. The co-occurrence of Lynch syndrome and SIT is extremely uncommon. Immune checkpoint inhibitors (ICIs) have demonstrated significant efficacy in treating microsatellite instability-high\/deficient mismatch repair (MSI-H\/dMMR) CRC. Tumors associated with Lynch syndrome frequently exhibit MSI-H, providing a theoretical basis for ICI use.<\/jats:p><\/jats:sec><jats:sec><jats:title>Case presentation<\/jats:title><jats:p>We report a case of bifocal colon cancer associated with Lynch syndrome and SIT. After seven cycles of sintilimab, the patient developed gastrointestinal perforation due to tumor regression, necessitating emergency surgery. The anatomical variations associated with SIT required the surgical team to adopt an alternative approach. Postoperatively, the patient continued sintilimab treatment for 2 years. In June 2024, he underwent a colostomy reversal and proximal colectomy. Pathological examination revealed a tumor regression grade (TRG) of 0, indicating complete pathological remission (pCR), with no recurrence or metastasis detected upon follow-up.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>The anatomical variations associated with SIT increase the complexity of surgical procedures. Advanced imaging modalities such as computed tomography (CT) and magnetic resonance imaging (MRI) are essential for assessing fine anatomical details and facilitating surgery. ICIs are an effective treatment option for Lynch syndrome-associated CRC, as demonstrated in this case. Future studies should investigate the optimal timing of immunotherapy, combination treatment strategies, and methods to mitigate immune-related toxicities. Such research will help develop comprehensive and personalized treatment plans for Lynch syndrome-associated CRC.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fimmu.2025.1571607","type":"journal-article","created":{"date-parts":[[2025,4,22]],"date-time":"2025-04-22T05:27:53Z","timestamp":1745299673000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":3,"title":["Pathological complete response after monotherapy with immune checkpoint inhibitors for bifocal colon cancer in a patient with lynch syndrome and situs inversus totalis: a case report"],"prefix":"10.3389","volume":"16","author":[{"given":"Jun","family":"Feng","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenbo","family":"Niu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuanyi","family":"Ding","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zheng","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jianfeng","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Baokun","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chenhui","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Feifei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guiying","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bin","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,4,22]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21834","article-title":"Global cancer statistics 2022: globocan estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA: A Cancer J clinicians"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21448","article-title":"Recent progress in lynch syndrome and other familial colorectal cancer syndromes","volume":"68","author":"Boland","year":"2018","journal-title":"CA: A Cancer J clinicians"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2022.08.058","article-title":"Lynch syndrome genetics and clinical implications","volume":"164","author":"Peltom\u00e4ki","year":"2023","journal-title":"Gastroenterology"},{"key":"B4","doi-asserted-by":"publisher","first-page":"e45","DOI":"10.1056\/NEJMicm1811002","article-title":"Situs inversus totalis","volume":"380","author":"Gentile","year":"2019","journal-title":"N Engl J Med"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1097\/cm9.0000000000003192","article-title":"Association of copy number variation in X chromosome-linked pnpla4 with heterotaxy and congenital heart disease","volume":"137","author":"Gao","year":"2024","journal-title":"Chin Med J (Engl)"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2023-063064","article-title":"Primary ciliary dyskinesia","volume":"153","author":"Wee","year":"2024","journal-title":"Pediatrics"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-pathol-042020-042741","article-title":"Immune checkpoint inhibitors for the treatment of cancer: clinical impact and mechanisms of response and resistance","volume":"16","author":"Bagchi","year":"2021","journal-title":"Annu Rev Pathol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1500596","article-title":"Pd-1 blockade in tumors with mismatch-repair deficiency","volume":"372","author":"Le","year":"2015","journal-title":"N Engl J Med"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(22)00197-8","article-title":"Pembrolizumab versus chemotherapy for microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer (Keynote-177): final analysis of a randomised, open-label, phase 3 study","volume":"23","author":"Diaz","year":"2022","journal-title":"Lancet Oncol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1038\/s10038-019-0609-1","article-title":"Clinical and genetic analysis of patients with primary ciliary dyskinesia caused by novel dnaaf3 mutations","volume":"64","author":"Guo","year":"2019","journal-title":"J Hum Genet"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.3390\/jcdd4040023","article-title":"The role of cerl2 in the establishment of left-right asymmetries during axis formation and heart development","volume":"4","author":"Belo","year":"2017","journal-title":"J Cardiovasc Dev Dis"},{"key":"B12","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1086\/380998","article-title":"Identification and functional analysis of zic3 mutations in heterotaxy and related congenital heart defects","volume":"74","author":"Ware","year":"2004","journal-title":"Am J Hum Genet"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1007\/s00595-009-4005-x","article-title":"Advanced cancer with situs inversus totalis associated with kif3 complex deficiency: report of two cases","volume":"40","author":"Haruki","year":"2010","journal-title":"Surg Today"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.4103\/jmas.jmas_311_21","article-title":"Three-dimensional laparoscopic treatment of situs inversus totalis combined with gastric cancer: case report with review of literature","volume":"19","author":"Huang","year":"2023","journal-title":"J Minim Access Surg"},{"key":"B15","doi-asserted-by":"publisher","first-page":"e8209","DOI":"10.1097\/md.0000000000008209","article-title":"Gastric cancer in a situs inversus totalis patient with multiple intestinal and vessel variations related to gastrectomy surgery: A case report and literature review","volume":"96","author":"Cao","year":"2017","journal-title":"Med (Baltimore)"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1007\/s11605-017-3576-x","article-title":"Robotic assisted distal gastrectomy for gastric cancer in a patient with situs inversus totalis: with video","volume":"21","author":"Alhossaini","year":"2017","journal-title":"J Gastrointest Surg"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.2147\/ijgm.S295444","article-title":"Situs inversus totalis: A clinical review","volume":"15","author":"Eitler","year":"2022","journal-title":"Int J Gen Med"},{"key":"B18","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1038\/s41436-019-0596-9","article-title":"Cancer risks by gene, age, and gender in 6350 carriers of pathogenic mismatch repair variants: findings from the prospective lynch syndrome database","volume":"22","author":"Dominguez-Valentin","year":"2020","journal-title":"Genet Med"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2014.04.001","article-title":"Guidelines on genetic evaluation and management of lynch syndrome: A consensus statement by the us multi-society task force on colorectal cancer","volume":"147","author":"Giardiello","year":"2014","journal-title":"Gastroenterology"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2015-309675","article-title":"Cancer incidence and survival in lynch syndrome patients receiving colonoscopic and gynaecological surveillance: first report from the prospective lynch syndrome database","volume":"66","author":"M\u00f8ller","year":"2017","journal-title":"Gut"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/s2468-1253(24)00091-8","article-title":"Clinical significance of combined tumour-infiltrating lymphocytes and microsatellite instability status in colorectal cancer: A systematic review and network meta-analysis","volume":"9","author":"Wankhede","year":"2024","journal-title":"Lancet Gastroenterology hepatology"},{"key":"B22","doi-asserted-by":"publisher","first-page":"e1515612","DOI":"10.1080\/2162402x.2018.1515612","article-title":"Immunoprofiles of colorectal cancer from lynch syndrome","volume":"8","author":"Walkowska","year":"2019","journal-title":"Oncoimmunology"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-023-00789-4","article-title":"Antigen presentation in cancer - mechanisms and clinical implications for immunotherapy","volume":"20","author":"Yang","year":"2023","journal-title":"Nat Rev Clin Oncol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/s2468-1253(22)00439-3","article-title":"Neoadjuvant pd-1 blockade with sintilimab in mismatch-repair deficient, locally advanced rectal cancer: an open-label, single-centre phase 2 study","volume":"8","author":"Chen","year":"2023","journal-title":"Lancet Gastroenterology hepatology"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-020-0805-8","article-title":"Neoadjuvant immunotherapy leads to pathological responses in mmr-proficient and mmr-deficient early-stage colon cancers","volume":"26","author":"Chalabi","year":"2020","journal-title":"Nat Med"},{"key":"B26","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/s2468-1253(21)00348-4","article-title":"Neoadjuvant pd-1 blockade with toripalimab, with or without celecoxib, in mismatch repair-deficient or microsatellite instability-high, locally advanced, colorectal cancer (Picc): A single-centre, parallel-group, non-comparative, randomised, phase 2 trial","volume":"7","author":"Hu","year":"2022","journal-title":"Lancet Gastroenterology hepatology"},{"key":"B27","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.immuni.2013.07.012","article-title":"Oncology meets immunology: the cancer-immunity cycle","volume":"39","author":"Chen","year":"2013","journal-title":"Immunity"},{"key":"B28","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1038\/s41568-023-00560-y","article-title":"Dynamics and specificities of T cells in cancer immunotherapy","volume":"23","author":"Oliveira","year":"2023","journal-title":"Nat Rev Cancer"},{"key":"B29","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1038\/s41573-018-0007-y","article-title":"Approaches to treat immune hot, altered and cold tumours with combination immunotherapies","volume":"18","author":"Galon","year":"2019","journal-title":"Nat Rev Drug Discov"},{"key":"B30","doi-asserted-by":"publisher","first-page":"1268","DOI":"10.1016\/j.ccell.2024.06.009","article-title":"Spatiotemporal single-cell analysis decodes cellular dynamics underlying different responses to immunotherapy in colorectal cancer","volume":"42","author":"Chen","year":"2024","journal-title":"Cancer Cell"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-002114","article-title":"Exploration of modified progression-free survival as a novel surrogate endpoint for overall survival in immuno-oncology trials","volume":"9","author":"Wang","year":"2021","journal-title":"J immunotherapy Cancer"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1002\/sim.9258","article-title":"Cancer immunotherapy trial design with random delayed treatment effect and cure rate","volume":"41","author":"Wu","year":"2022","journal-title":"Stat Med"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.Ccr-16-3065","article-title":"Immuno-oncology trial endpoints: capturing clinically meaningful activity","volume":"23","author":"Anagnostou","year":"2017","journal-title":"Clin Cancer Res"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-002435","article-title":"Society for immunotherapy of cancer (Sitc) clinical practice guideline on immune checkpoint inhibitor-related adverse events","volume":"9","author":"Brahmer","year":"2021","journal-title":"J immunotherapy Cancer"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.32132","article-title":"A systematic review of adverse events in randomized trials assessing immune checkpoint inhibitors","volume":"145","author":"Arnaud-Coffin","year":"2019","journal-title":"Int J Cancer"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1016\/j.gie.2019.09.009","article-title":"Immune checkpoint inhibitor-related luminal gi adverse events","volume":"90","author":"Kr\u00f6ner","year":"2019","journal-title":"Gastrointest Endosc"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2012.41.6750","article-title":"Management of immune-related adverse events and kinetics of response with ipilimumab","volume":"30","author":"Weber","year":"2012","journal-title":"J Clin Oncol"},{"key":"B38","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1186\/s12916-015-0455-8","article-title":"Immune related adverse events associated with anti-ctla-4 antibodies: systematic review and meta-analysis","volume":"13","author":"Bertrand","year":"2015","journal-title":"BMC Med"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1080\/2162402x.2017.1344805","article-title":"Incidence of immune checkpoint inhibitor-related colitis in solid tumor patients: A systematic review and meta-analysis","volume":"6","author":"Wang","year":"2017","journal-title":"Oncoimmunology"},{"key":"B40","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/s1470-2045(16)30624-6","article-title":"Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (Checkmate 012): results of an open-label, phase 1, multicohort study","volume":"18","author":"Hellmann","year":"2017","journal-title":"Lancet Oncol"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1200\/jco.21.00174","article-title":"Five-year outcomes with pembrolizumab versus chemotherapy for metastatic non-small-cell lung cancer with pd-L1 tumor proportion score \u2265 50","volume":"39","author":"Reck","year":"2021","journal-title":"J Clin Oncol"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1200\/jco.19.02446","article-title":"Long-term outcomes and retreatment among patients with previously treated, programmed death-ligand 1\u2013Positive, advanced non\u2013Small-cell lung cancer in the keynote-010 study","volume":"38","author":"Herbst","year":"2020","journal-title":"J Clin Oncol"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1200\/jco.20.00131","article-title":"Continuous versus 1-year fixed-duration nivolumab in previously treated advanced non-small-cell lung cancer: checkmate 153","volume":"38","author":"Waterhouse","year":"2020","journal-title":"J Clin Oncol"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2023.1891","article-title":"Association between duration of immunotherapy and overall survival in advanced non-small cell lung cancer","volume":"9","author":"Sun","year":"2023","journal-title":"JAMA Oncol"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2400634","article-title":"Neoadjuvant immunotherapy in locally advanced mismatch repair-deficient colon cancer","volume":"390","author":"Chalabi","year":"2024","journal-title":"N Engl J Med"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1001\/jamasurg.2023.7996","article-title":"Total neoadjuvant therapy with pd-1 blockade for high-risk proficient mismatch repair rectal cancer","volume":"159","author":"Li","year":"2024","journal-title":"JAMA Surg"},{"key":"B47","doi-asserted-by":"publisher","first-page":"60","DOI":"10.6004\/jnccn.2022.7060","article-title":"Neoadjuvant immunotherapy leads to major response and low recurrence in localized mismatch repair-deficient colorectal cancer","volume":"21","author":"Xiao","year":"2023","journal-title":"J Natl Compr Canc Netw"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1571607\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,22]],"date-time":"2025-04-22T05:27:54Z","timestamp":1745299674000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1571607\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,22]]},"references-count":47,"alternative-id":["10.3389\/fimmu.2025.1571607"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1571607","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,22]]},"article-number":"1571607"}}